Current updates on the structural and functional aspects of the CRISPR/Cas13 system for RNA targeting and editing: A next‑generation tool for cancer management (Review)
International Journal of Oncology · 06.05.2025 · 66 (5) · 1-21
DOI: 10.3892/ijo.2025.5748 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Oncology, online erschienen am 06.05.2025. Verfasst von Khaled S Allemailem und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Neoplasms, Gene Editing. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
For centuries, a competitive evolutionary race between prokaryotes and related phages or other mobile genetic elements has led to the diversification of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR‑associated sequence (Cas) genome‑editing systems. Among the different CRISPR/Cas systems, the CRISPR/Cas9 system has been widely studied for its precise DNA manipulation; however, due to certain limitations of direct DNA targeting, off‑target effects and delivery challenges, researchers are looking to perform transient knockdown of gene expression by targeting RNA. In this context, the more recently discovered type VI CRISPR/Cas13 system, a programmable single‑subunit RNA‑guided endonuclease system that has the capacity to target and edit any RNA sequence of interest, has emerged as a powerful platform to modulate gene expression outcomes. All the Cas13 effectors known so far possess two distinct ribonuclease activities. Pre‑CRISPR RNA processing is performed by one RNase activity, whereas the two higher eukaryotes and prokaryotes nucleotide‑binding domains provide the other RNase activity required for target RNA degradation. Recent innovative applications of the type VI CRISPR/Cas13 system in nucleic acid detection, viral interference, transcriptome engineering and RNA imaging hold great promise for disease management. This genome editing system can also be employed by the Specific High Sensitivity Enzymatic Reporter Unlocking platform to identify any tumor DNA. The discovery of this system has added a new dimension to targeting, tracking and editing circulating microRNA/RNA/DNA/cancer proteins for the management of cancer. However, there is still a lack of thorough understanding of the mechanisms underlying some of their functions. The present review summarizes the recent updates on the type VI CRISPR/Cas system in terms of its structural and mechanistic properties and some novel applications of this genome‑editing tool in cancer management. However, some issues, such as collateral degradation of bystander RNA, impose major limitations on its in vivo application. Furthermore, additional challenges and future prospects for this genome editing system are described in the present review.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia.
- Department of Biology, College of Science, University of Hafr Al Batin, Hafr Al Batin 31991, Saudi Arabia.
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 11433, Saudi Arabia.
- Department of Laboratory and Blood Bank, King Fahd Specialist Hospital, Tabuk 47717, Saudi Arabia.
- Department of Laboratory and Blood Bank, Maternity and Children Hospital, Tabuk 47717, Saudi Arabia.
- Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia.
Zitieren
APA
Allemailem, K. S., Rahmani, A. H., Almansour, N. M., Aldakheel, F. M., Albalawi, G. M., Albalawi, G. M., & Khan, A. A. (2025). Current updates on the structural and functional aspects of the CRISPR/Cas13 system for RNA targeting and editing: A next‑generation tool for cancer management (Review). International Journal of Oncology, 66(5), 1-21. https://doi.org/10.3892/ijo.2025.5748
Vancouver
Allemailem KS, Rahmani AH, Almansour NM, Aldakheel FM, Albalawi GM, Albalawi GM, et al. Current updates on the structural and functional aspects of the CRISPR/Cas13 system for RNA targeting and editing: A next‑generation tool for cancer management (Review). International Journal of Oncology. 2025;66(5):1-21. doi:10.3892/ijo.2025.5748
BibTeX
@article{Allemailem2025,
author = {Allemailem, Khaled S and Rahmani, Arshad Husain and Almansour, Nahlah Makki and Aldakheel, Fahad M and Albalawi, Ghadah Mohammad and Albalawi, Ghadeer Mohammed and Khan, Amjad Ali},
title = {Current updates on the structural and functional aspects of the CRISPR/Cas13 system for RNA targeting and editing: A next‑generation tool for cancer management (Review)},
journal = {International Journal of Oncology},
year = {2025},
volume = {66},
number = {5},
pages = {1--21},
doi = {10.3892/ijo.2025.5748}
}
EUVIMED